Global Cord Blood Corporation Announces Receipt of Blue Ocean Petition
HONG KONG, May 11, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company has received a copy of a petition that was filed with the Grand Court of the Cayman Islands by Blue...
Foodmate Announced Opening of a New Factory
SHANGHAI, May 9, 2022 /PRNewswire/ -- Foodmate, an innovative Chinese enterprise engaged in R&D, manufacture and sales of a diversified product portfolio which includes natural, nutritious food ingredients such as Gelatin, Hydrocolloids, Collagen Peptides, Functional animal proteins, Calorie-free Sugar Substitute, has announced the rollout of its Phase II Plant in May 2022. New modern factory The new state-of-the-art facility...
Bridge Biotherapeutics to Announce Updated Data from its Phase 1 Study of BBT-176 in Advanced Non-Small Cell Lung Cancer in an Oral Presentation at IASLC 2022 World Conference on...
Data analysis to explore demonstrated anti-tumor activity of BBT-176, a fourth generation EGFR TKI, in advanced non-small cell lung cancer SEONGNAM, South Korea , May 10 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, announced it will deliver an oral presentation highlighting the...
Havas Health & You Launches Patient Engagement Consultancy, Repositioning Influencer Marketing Through a First-of-Its-Kind Conversational Analysis Platform
Havas Voice, Powered by Atlas Health, Identifies the Center of Health Conversations to Elevate Brand Engagement By Activating Authentic Patient Voices NEW YORK, May 10, 2022 /PRNewswire/ -- To drive health and wellness brands towards authentic patient centricity, Havas Health & You (HH&Y) has launched Havas Voice, powered by Atlas Health, a patient...
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen’s CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated trial of CT041 have been published in Nature Medicine (https://www.nature.com/articles/s41591-022-01800-8), which...
ProSomnus®, Leader in Patient-Preferred Sleep Apnea Therapy, to be Listed on Nasdaq Through Business Combination with Lakeshore Acquisition I Corp.
ProSomnus is a pioneer of precision intraoral devices, a new option for treating mild to moderate obstructive sleep apnea (OSA) A number of scientific studies indicate ProSomnus precision intraoral devices as the most effective treatment for mild and moderate obstructive sleep apnea Obstructive sleep apnea is a chronic medical disease linked with significant comorbidities that affects approximately...
Bora Pharmaceuticals acquires Eden Biologics CDMO Assets
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market TAIPEI, May 10, 2022 /PRNewswire/ -- Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of Bora Biologics Co., Ltd., a CDMO platform for biologics. Besides Bora, investors into the new entity include Taishin...
Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the Company will release the progress of the next-generation anti-CTLA-4 antibody HBM4003 studies of monotherapy and...
Unprecedented miracle of resolving Blood Shortage crisis from COVID-19
SEOUL, South Korea, May 10, 2022 /PRNewswire/ -- After the start of blood donation, '18478' people participated for 2 weeks. The blood donation of Shincheonji Church of Jesus, which began with the goal of solving the blood shortage in Korea, has achieved an unprecedented miracle. This is more than 3 times the average daily use of blood in...
OMRON Healthcare Unveils Long-term Corporate Vision, “Going for ZERO, Preventive Care for Health of Society”
- Aiming to Realize 3 Zeros: "Zero Cerebrovascular and Cardiovascular Events," "Zero Aggravation of Respiratory Diseases" and "Zero Restrictions on Daily Activities Due to Chronic Pain" - KYOTO, Japan, May 10, 2022 /PRNewswire/ -- In March 2022, OMRON Group announced a new long-term vision, "Shaping the Future 2030" (hereafter referred to as SF2030). In its commitment to achieving this vision for...
